Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842073 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL14093032 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31482164 | 0.98 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL10129028 | 0.93 | SSTR4 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL14092960 | 0.93 | SSTR4 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL25595886 | 0.91 | SSTR4 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL27361436 | 0.91 | SSTR4 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL23260533 | 0.86 | SSTR4 (0.35) | SSTR4 | |
| SCHEMBL22433108 | 0.84 | SMN1; SMN2 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1104693 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SLC6A1 4353/4885SLC6A11 3847/4885TSHR 1047/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | SLC6A1 4791/4885SLC6A11 4711/4885TSHR 3447/4885 |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SLC6A1 4353/4885SLC6A11 3847/4885TSHR 1047/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | SLC6A1 3194/4885SLC6A11 3910/4885TSHR 3613/4885 |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | SLC6A1 1580/4885SLC6A11 1978/4885TSHR 3349/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SLC6A1 4785/4885SLC6A11 4756/4885TSHR 1082/4885 |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SLC6A1 4353/4885SLC6A11 3847/4885TSHR 1047/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | SLC6A1 4850/4885SLC6A11 4856/4885TSHR 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.